MeSH term
Frequency | Condition_Probility | Cell Line | 6 | 0.0 |
Genotype | 9 | 0.0 |
Humans | 67 | 0.0 |
Receptors, Interleukin/metabolism | 3 | 5.0 |
Recombinant Proteins/metabolism | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 41 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 19 | 0.0 |
*Variation (Genetics) | 3 | 0.0 |
English Abstract | 2 | 0.0 |
Male | 15 | 0.0 |
Adolescent | 6 | 0.0 |
Animals | 16 | 0.0 |
Child | 10 | 0.0 |
Child, Preschool | 6 | 0.0 |
Th2 Cells/*immunology | 3 | 2.0 |
Female | 12 | 0.0 |
Interleukin-13/genetics | 5 | 55.0 |
*Polymorphism, Genetic | 3 | 0.0 |
Receptors, Interleukin-4/genetics | 2 | 18.0 |
Comparative Study | 9 | 0.0 |
Asthma/*genetics/immunology | 2 | 12.0 |
*Epistasis, Genetic | 3 | 12.0 |
Exons/genetics | 2 | 0.0 |
Immunoglobulin E/blood | 4 | 2.0 |
Interleukin-13/*genetics | 12 | 92.0 |
Middle Aged | 7 | 0.0 |
Odds Ratio | 2 | 0.0 |
Phenotype | 5 | 0.0 |
Receptors, Interleukin-4/*genetics | 7 | 29.0 |
Alleles | 4 | 0.0 |
Cytokines/*genetics | 5 | 3.0 |
Gene Frequency | 7 | 0.0 |
Haplotypes | 5 | 0.0 |
Linkage (Genetics) | 3 | 0.0 |
Polymorphism, Single Nucleotide | 4 | 0.0 |
Cell Survival/drug effects | 2 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Mutation | 2 | 0.0 |
Tumor Cells, Cultured/drug effects | 3 | 0.0 |
Adult | 5 | 0.0 |
Aged | 5 | 0.0 |
Cohort Studies | 5 | 0.0 |
Gene Expression | 2 | 0.0 |
Interleukin-4/genetics | 2 | 5.0 |
Interleukin-5/genetics | 3 | 23.0 |
Immunophenotyping | 3 | 0.0 |
Interferon Type II/secretion | 2 | 1.0 |
Cells, Cultured | 2 | 0.0 |
Down-Regulation | 2 | 0.0 |
Disease Progression | 2 | 0.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Interleukin-13/*metabolism | 3 | 25.0 |
Interleukin-4/metabolism | 3 | 3.0 |
Receptors, Interleukin/*genetics | 4 | 12.0 |
Transcription, Genetic | 4 | 0.0 |
Tumor Cells, Cultured | 9 | 0.0 |
*Chromosomes, Human, Pair 5 | 3 | 1.0 |
Dermatitis, Atopic/*genetics | 2 | 16.0 |
Immunoglobulin E/*blood | 2 | 3.0 |
Infant, Newborn | 3 | 0.0 |
Variation (Genetics) | 5 | 0.0 |
Amino Acid Sequence | 8 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/genetics | 2 | 7.0 |
Molecular Sequence Data | 8 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Blotting, Western | 2 | 0.0 |
Cell Differentiation | 3 | 0.0 |
DNA/metabolism | 2 | 0.0 |
Immunohistochemistry | 4 | 0.0 |
Mice | 7 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Mice, Inbred C57BL | 3 | 0.0 |
*Nuclear Proteins | 2 | 0.0 |
Promoter Regions (Genetics) | 4 | 0.0 |
T-Lymphocytes/metabolism | 3 | 1.0 |
Time Factors | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
Interleukin-5/*genetics | 2 | 16.0 |
Flow Cytometry | 2 | 0.0 |
Mice, Transgenic | 2 | 0.0 |
Base Sequence | 6 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
DNA/genetics | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
Gene Expression Regulation/*physiology | 2 | 0.0 |
Glioblastoma/*metabolism | 2 | 6.0 |
Cytokines/immunology/pharmacology | 2 | 28.0 |
Mitogens/immunology/pharmacology | 2 | 40.0 |
Cell Culture Techniques | 2 | 0.0 |
*Carrier Proteins | 2 | 0.0 |
Pseudomonas aeruginosa | 2 | 11.0 |
*ADP Ribose Transferases | 3 | 3.0 |
Exotoxins/*pharmacology | 2 | 8.0 |
Receptors, Interleukin/*metabolism | 3 | 9.0 |
*Virulence Factors | 3 | 3.0 |
Interleukin-13/metabolism | 3 | 18.0 |
Interleukin-4/*metabolism | 2 | 5.0 |
Receptors, Interleukin-4 | 5 | 7.0 |
Cell Division/drug effects | 2 | 0.0 |
Cytokines/*pharmacology | 2 | 0.0 |
Drug Synergism | 2 | 0.0 |
Phosphorylation | 2 | 0.0 |
Tyrosine/metabolism | 2 | 0.0 |
Circular Dichroism | 2 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Protein Structure, Secondary | 2 | 0.0 |
Trans-Activators/*metabolism | 2 | 0.0 |
*Bacterial Toxins | 2 | 1.0 |
Binding Sites | 2 | 0.0 |
Binding, Competitive | 2 | 0.0 |
Fetal Blood/immunology | 2 | 2.0 |
Interleukin-13/*pharmacology | 2 | 4.0 |
Aged, 80 and over | 2 | 0.0 |
Immunosuppressive Agents/*therapeutic use | 2 | 1.0 |
Asthma/genetics/immunology | 2 | 50.0 |
Hypersensitivity, Immediate/*genetics/*immunology | 3 | 75.0 |
Infant | 3 | 0.0 |
Case-Control Studies | 3 | 0.0 |
Germany | 2 | 0.0 |
Interleukin-4/*genetics | 7 | 14.0 |
Risk Factors | 2 | 0.0 |
Chromosomes, Human, Pair 5 | 2 | 1.0 |
Trans-Activators/metabolism | 2 | 0.0 |
Interleukin-13 | 2 | 40.0 |
Pilot Projects | 2 | 0.0 |
Polymorphism, Genetic | 2 | 0.0 |
Polymerase Chain Reaction | 3 | 0.0 |
*Polymorphism, Single Nucleotide | 2 | 0.0 |
DNA Primers | 2 | 0.0 |
